# 3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025

November 3, 2025 at 4:01 PM EST

COPENHAGEN, Denmark, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its data showing sustained improvements in renal function, continued normalization of urine calcium handling, and continued safety and efficacy in adults with hypoparathyroidism treated with TransCon PTH (palopegteriparatide) through Year 3 of the Phase 2 PaTH Forward and Phase 3 PaTHway trials will be shared during Kidney Week 2025, the annual meeting of the American Society for Nephrology being held in Houston from November 5-9.

| | |
|---|---|
| Thursday<br>November 6<br>10 a.m. – 12 p.m.<br>Convention Center<br>Exhibit Hall | Abstract and Poster #TH-PO0227<br><br>**Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 3-Year Results from the PaTH Forward and PaTHway Trials**<br><br>*Gosmanova, Schwarz,Rejnmark et al*<br>*Presentation on November 6 by Dr. Elvira Gosmanova*<br><br>*The abstract is also available in the Journal of the American Society of Nephrology 36(10S):10.1681/ASN.20253yamgex4, October 2025.* \| *DOI: 10.1681/ASN.20253yamgex4* |

"We are pleased to share this data reinforcing the benefits of long-term treatment with TransCon PTH on renal function," said Aimee Shu, M.D., Executive Vice President of Endocrine & Rare Disease Medical Science and Chief Medical Officer at Ascendis Pharma. "Our goal at this pre-eminant nephrology meeting is to expand awareness and scientific knowledge of TransCon PTH, the kidney's role in a healthy parathyroid axis, and the importance of delivering physiological levels of PTH for overall kidney health."

TransCon PTH is a prodrug of PTH (1-34), administered once daily, designed to provide active parathyroid hormone (PTH) within the physiological range for 24 hours/day. TransCon PTH is approved as YORVIPATH® in the United States, European Union, and European Economic Area as a treatment for adults with hypoparathyroidism.

**About Hypoparathyroidism**
Hypoparathyroidism is an endocrine disease caused by insufficient levels of parathyroid hormone (PTH), the primary regulator of calcium and phosphate balance in the body, acting directly on bone and kidney and indirectly on the intestine. Individuals with hypoparathyroidism may experience a range of severe and potentially life-threatening short-term and long-term complications, including neuromuscular irritability, renal complications, extra-skeletal calcifications, and cognitive impairment. Post-surgical hypoparathyroidism accounts for the majority of cases (70-80%), while other etiologies include autoimmune and idiopathic causes.

**About Ascendis Pharma A/S**
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.

**Forward-Looking Statements**
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis' future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis' plan to present TransCon PTH data during Kidney Week 2025, (ii) Ascendis' goal to expand awareness of TransCon PTH as an important treatment option, (iii) Ascendis' ability to apply its TransCon technology platform to make a meaningful difference for patients, and (iv) Ascendis' application of its TransCon technologies to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis' products and product candidates; unforeseen safety or efficacy results in Ascendis' development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis' development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis' business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis' ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors, including tariffs and trade policies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis' business in general, see Ascendis' Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 12, 2025, and Ascendis' other future reports filed with, or submitted to, the SEC.

Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

*Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and YORVIPATH® are trademarks owned by the Ascendis Pharma group. © November 2025 Ascendis Pharma A/S.*

**Investor Contacts:**
Chad Fugere
Ascendis Pharma
ir@ascendispharma.com

Patti Bank
ICR Healthcare
+1 (415) 513-1284
patti.bank@icrhealthcare.com

**Media Contact:**
Melinda Baker
Ascendis Pharma
media@ascendispharma.com

Source: Ascendis Pharma